Celldex Therapeutics, Inc. CLDX
31.10
(0.38)
(1.21%)
as of 25 Sep
- Market cap
- $2.5B
- P/E
- 0.0×
Follow CLDX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (43.88%) | (48.94%) | (40.62%) | (32.44%) |
+8 more TTM periods Free account |
|
| (40.76%) | (45.36%) | (37.63%) | (30.51%) | ||
ROIC |
0.00% | (4,051.27%) | (1,828.59%) | (1,057.79%) | |
Return on Tangible Assets |
(44.63%) | (68.32%) | (52.91%) | (39.90%) | |
Average Days of Receivables |
94.64 | 53.81 | 270.40 | 0.00 | |
Free Cash Flow per Share |
(3.11) | (3.40) | (3.22) | (2.74) | |
Free Cash Flow |
(242.10) | (226.25) | (213.66) | (181.67) | |
Capital Expenditures |
(6.54) | (4.09) | (2.71) | (2.19) | |
Piotroski F-Score |
1.00 | 2.00 | 1.00 | — | |
| Other line items | |||||
Cash ROIC |
(16.43%) | (24.48%) | (20.15%) | (15.19%) | |
Accounts Receivable Turnover |
5.54 | 2.41 | 2.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
31,432.58% | 17,016.73% | 9,010.07% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
5,318.94% | 2,850.45% | 1,611.69% | 0.00% | |
Share Based Compensation of Revenue |
3,905.41% | 2,270.77% | 1,331.51% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.78 | 0.78 | 0.82 | 0.80 | |
Depreciation/Fixed assets |
(0.09) | (0.12) | (0.46) | (1.03) | |
Capex/Depreciation |
7.86 | 4.80 | 1.10 | 0.44 | |
Revenue per Share |
0.01 | 0.02 | 0.04 | 0.00 | |
Operating CF per Share |
(3.03) | (3.34) | (3.18) | (2.70) | |
Capex per Share |
(0.08) | (0.06) | (0.04) | (0.03) | |
Capex to Sales |
7.37 | 2.62 | 1.00 | 0.00 | |
Net Profit Margin |
(33,883.77%) | (18,182.44%) | (9,513.13%) | 0.00% |
Columns are period end dates